Objectives: To provide guidance for the management of mood disorders, based on scientific
evidence supplemented by expert clinical consensus and formulate recommendations to …

Although the field of pharmacogenetics has existed for decades, practioners have been slow
to implement pharmacogenetic testing in clinical care. Numerous publications describe the …

A critical review of the limited available evidence and the authors' experience and judgment
are used to summarize the role of cytochrome P450 (CYP) genetic variants in the …

Objective Major depressive disorder (MDD) is projected to be a leading cause of disability
globally by 2030. Only a minority of patients remit with antidepressants. If assay of …

Haplotypes are often critical for the interpretation of genetic laboratory observations into
medically actionable findings. Current massively parallel DNA sequencing technologies …

Abstract Introduction. Cytochrome P450 2D6 (CYP2D6) is a member of the cytochrome
P450 (CYP) superfamily involved in the biotransformation of drugs and substances of abuse …

Adverse drug reactions (ADRs) are a major public health concern and cause significant
patient morbidity and mortality. Pharmacogenomics is the study of how genetic …

Abstract CYP2D6 metabolizes nearly 25% of clinically used drugs. Genetic polymorphisms
cause large inter-individual variability in CYP2D6 enzyme activity and are currently used as …

Personalized medicine, with the aim of safely, effectively, and cost-effectively targeting
treatment to a prespecified patient population, has always been a long-time goal within …

Numerous studies in the field of psychopharmacological treatment have investigated the
possible contribution of genetic variability between individuals to differences in drug efficacy …